Abstract:Multiple myeloma remains incurable to date; therefore, new biologically target-based therapies are urgently needed. Our previous studies have showed that the antimalarial dihydroartemisinin possessed antiangiogenic activity in solid tumors. The present study evaluated the effect of dihydroartemisinin on human multiple myeloma-induced angiogenesis under hypoxia and elucidated its mechanism of action. An in-vivo chicken chorioallantoic membrane model was used to examine the effect of dihydroartemisinin on multiple myeloma-induced angiogenesis. Compared with conditioned medium of control, conditioned medium from human multiple myeloma RPM18226 cells pretreated with 3 mu mol/l dihydroartemisinin in hypoxia was observed to reduce microvessel growth on chicken chorioallantoic membranes by approximately 28.6% (P < 0.05). The level of vascular endothelial growth factor in conditioned medium was determined by enzyme-linked immunosorbent assay. The results confirmed that 3 mu mol/l dihydroartemisinin could significantly decrease vascular endothelial growth factor secretion by RPM18226 cells (P < 0.05), which correlated well with the reduction of multiple myeloma-induced angiogenesis on chicken chorioallantoic membranes. Western blot and reverse transcription-polymerase chain reaction results revealed that dihydroartemisinin downregulated the expression of vascular endothelial growth factor in RPM18226 cells in hypoxia. In addition, we demonstrated that dihydroartemisinin reduced extracellular signal-regulated kinase 1/2 activation and inhibited growth of RPM18226 cells under hypoxic conditions. Therefore, we concluded that dihydroartemisinin, which is already used to treat malaria and is well tolerated, possesses potential as an antiangiogenic drug in multiple myeloma therapy and thereby may improve patient outcome.

Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro.

Inhibitory effect of artesunate on angiogenesis

Antimalarial Dihydroartemisinin Also Inhibits Angiogenesis.

Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1.

Artesunate Reduces Chicken Chorioallantoic Membrane Neovascularisation and Exhibits Antiangiogenic and Apoptotic Activity on Human Microvascular Dermal Endothelial Cell

Inhibition of artesunate on angiogenesis of deciduoma and marrow in pseudopregnant rats

Anti-malarial drug: the emerging role of artemisinin and its derivatives in liver disease treatment

EFFECTS OF ARTESUNATE ON GROWTH AND FORMATION OF VESSEL IN ANGIOGENESIS

Ation mechanism of dihydroartemisinin combined with COX-2 inhibitor in S180 carcinoma

Design of novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties

Dihydroartemisinin Induces Apoptosis of Cervical Cancer Cells Via Upregulation of RKIP and Downregulation of Bcl-2.

Progress on the Study of Anti-tumor Mechanisms of Dihydroartemisinin

Dihydroartemisinin inhibits angiogenesis in breast cancer via regulating VEGF and MMP-2/-9

Dihydroartemisinin Inhibits Angiogenesis Induced by Multiple Myeloma RPMI8226 Cells under Hypoxic Conditions Via Downregulation of Vascular Endothelial Growth Factor Expression and Suppression of Vascular Endothelial Growth Factor Secretion

Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemia K562 cells

[Dihydroartemisinin Inhibits the Expression of Vascular Endothelial Growth Factor in K562 Cells].

Study on the structure-activity relationship of dihydroartemisinin derivatives: Discovery, synthesis, and biological evaluation of dihydroartemisinin-bile acid conjugates as potential anticancer agents

Novel Dihydroartemisinin Dimer Containing Nitrogen Atoms Inhibits Growth of Endometrial Cancer Cells and May Correlate with Increasing Intracellular Peroxynitrite.

Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug

Semi-synthetic product dihydroartemisinin inhibited fibronectin-1 and integrin-β1 and interfered with the migration of HCCLM6 cells via PI3K-AKT pathway

Dihydroartemisinin improves the efficiency of chemotherapeutics in lung carcinomas in vivo and inhibits murine Lewis lung carcinoma cell line growth in vitro